FUNDAMENTALS
EdgeFII/DII
GLENMARKGlenmark Pharma
₹2,648.00+1.51%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
GLENMARKNSE · EquityPharmaceuticals

Glenmark Pharma

ISIN
INE935A01035
Instrument key
NSE_EQ|INE935A01035
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹2,648.00+39.50 · +1.51%
Day rangecircuit ₹2,383.20 – ₹2,912.80
2,601.90
2,657.70

as of 22/11/2026, 1:57:58 pm

Open
₹2,607.90
Day high
₹2,657.70
Day low
₹2,601.90
Prev. close
₹2,608.50
Volume
5.40 L
VWAP
₹2,636.16

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

1 week · 15-minute candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M6M1Y5YMAX
Change · 1W
-0.53%
2,662.10 → 2,648.00
Period high
₹2,691.50
18/11/2026
Period low
₹2,600.20
17/11/2026
From high
-1.62%
+1.84% from low
Avg volume
21.3K
26.65 L total
Candles
125
56 up / 68 down
20 Nov 2026O 2,648.00H 2,648.00L 2,648.00C 2,648.00Vol 3.6K
SMA 20SMA 50Averages need 50 candles before they begin
Candle data125 rows of open, high, low, close and volumeShowHide
20 Nov 20262,648.002,648.002,648.002,648.000.00%0.003.6K
20 Nov 20262,641.102,650.702,637.502,648.00+0.26%13.2044.3K
20 Nov 20262,644.502,644.502,635.502,641.10-0.13%9.0021.2K
20 Nov 20262,643.802,648.002,641.802,644.50+0.03%6.2011.9K
20 Nov 20262,644.202,649.002,643.102,643.90-0.01%5.907.5K
20 Nov 20262,646.402,647.802,640.002,644.30-0.08%7.8027.9K
20 Nov 20262,646.702,647.802,645.002,646.00-0.03%2.805.8K
20 Nov 20262,652.802,653.202,646.302,646.70-0.23%6.907.3K
20 Nov 20262,654.502,657.702,652.002,653.80-0.03%5.7011.7K
20 Nov 20262,645.302,654.902,638.902,654.50+0.35%16.0053.8K

Historical price and volume data · Showing 1–10 of 125

1 / 13

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

51.5
Company
51.5
Sector
-45.69

Worse than sector by 213%

P/B

Price ÷ book value per share

6.67
Company
6.67
Sector
4.2

Worse than sector by 59%

ROA

Net income ÷ total assets

6.78%
Company
6.78%
Sector
1.19%

Better than sector by 470%

ROE

Net income ÷ shareholders' equity

18.07%
Company
18.07%
Sector
-0.4%

Better than sector by 4618%

ROCE

EBIT ÷ capital employed

19.86%
Company
19.86%
Sector
15.44%

Better than sector by 29%

Quick Ratio

Liquid assets ÷ current liabilities

1.23
Company
1.23
Sector
4.78

Worse than sector by 74%

EV/EBITDA

Enterprise value ÷ EBITDA

27.11
Company
27.11
Sector
22.9

Worse than sector by 18%

04/Business

About the company

Sector: Pharmaceuticals

Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.

Sector market cap (INR)
₹74,733 Cr

reported in crore

Sector market cap (USD)
$8.30B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Consolidated income statement

Quarterly figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Sep 2026
₹4,250 Cr
+4.06% vs Jun 2026
Net profit · Sep 2026
₹264 Cr
-45.36% vs Jun 2026
Operating margin
8.0%
was 15.8%
Revenue CAGR · 4p
2.5%
profit -13.2% · op -14.1%
Filed order
Revenue4,2504,0843,9603,945
Revenue growthreported4.1%3.1%0.4%—
Operating profit338643388534
Operating profit growthreported-47.4%65.9%-27.4%—
Operating marginderived8.0%15.8%9.8%13.5%
Net profit264483301403
Net profit growthreported-45.4%60.2%-25.3%—
Net marginderived6.2%11.8%7.6%10.2%
EPS — basic₹/share, annual——48.26—

Figures in ₹ crore. Margin rows are computed from the reported values.

Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
Filed order
Revenue16,98313,32211,81311,583
Other Income461114840289
Total Revenue17,44313,43512,65311,872
Total Expenses13,19211,66311,71610,866
Profit Before Tax1,9851,39937240
Tax6233521,867329
Profit After Tax1,3621,047-1,831-90
EPS - Basic48.2637.11-53.2210.53
EPS - Diluted48.2437.11-53.2210.53

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.

06/Balance sheet

Consolidated balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹19,908 Cr
+24.04% YoY
Total liabilities
₹9,396 Cr
Net worth
₹10,512 Cr
Liabilities ÷ assets
47.2%
lower means a lighter balance sheet
Filed order
Total assets19,90816,05014,35919,372
Total liabilities9,3967,2006,5119,532
Net worthderived10,5128,8497,8489,839
Liabilities ÷ assetsderived47.2%44.9%45.3%49.2%
Asset growthderived24.0%11.8%-25.9%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets8,6086,7546,9318,646
Current Assets11,3009,2957,42810,726
Total Assets19,90816,05014,35919,372
Current Liabilities6,3765,9675,8195,105
Net Current Asset4,9233,3281,6105,620
Non-Current Liabilities3,0201,2336924,427
Equity Capital10,5128,8497,8489,839
Total Equity & Liabilities19,90816,05014,35919,372

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Consolidated cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹3,445 Cr
+516.27% YoY
Investing
-₹1,283 Cr
Financing
-₹2,709 Cr
Free cash flow
₹2,162 Cr
operating + investing
Filed order
Operating activities3,445-828-265625
Operating changereported516.3%-211.8%-142.4%—
Investing activities-1,28324,561-528
Investing changereported-61498.6%-100.0%963.0%—
Financing activities-2,709787-3,906-77
Financing changereported-444.2%120.2%-4942.8%—
Net cash flowderived-547-3838919
Free cash flowoperating + investing2,162-8264,29597

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax1,9851,399569868
Income before WC changes4,6752,3461,5792,340
Change in Assets-3,152-1,715-63-1,241
Change in Liabilities2,705-779-734166
Change in WC-447-2,494-797-1,074
Cash flow from Operations3,445-828-265625
Cash flow from Investing-1,28324,561-528
Cash flow from Financing-2,709787-3,906-77
Total Cash Flow-547-3838919
Cash (Start of the year)1,6761,6581,4431,411
Cash (End of the year)1,1751,6761,6581,443

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
46.65%
0.00 pts QoQ
FII
21.51%
+0.62 pts QoQ
DII (other)
2.02%
+0.17 pts QoQ
Mutual funds
15.61%
-1.15 pts QoQ
Retail & others
14.21%
+0.36 pts QoQ
Filed order
Promoters46.6%46.6%46.6%46.6%
FII21.5%20.9%20.3%19.2%
DII (other)2.0%1.9%2.5%2.2%
Mutual funds15.6%16.8%16.8%17.9%
Retail & others14.2%13.8%13.7%14.1%
Promoters — QoQ changepts, derived0.0%0.0%0.0%—
FII — QoQ changepts, derived0.6%0.6%1.1%—
DII (other) — QoQ changepts, derived0.2%-0.6%0.3%—
Mutual funds — QoQ changepts, derived-1.2%-0.0%-1.1%—
Retail & others — QoQ changepts, derived0.4%0.1%-0.3%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

DividendFinal₹2.50250.0%31 Aug 202631 Aug 202629 May 2026

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
TORNTPHARMTorrent Pharmaceuticals LPharmaceuticals₹4,689.50+1.70%2.00 L₹1,78,727 Cr$19.86B
LAURUSLABSLaurus Labs LimitedPharmaceuticals₹2,294.60-0.49%8.79 L₹1,24,002 Cr$13.78B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
MANKINDMankind Pharma LimitedPharmaceuticals₹2,665.00+1.37%4.56 L₹1,09,870 Cr$12.21B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
LUPINLupin LimitedPharmaceuticals₹2,014.00+0.76%6.31 L₹91,916 Cr$10.21B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

5102050
  • Thumbnail: SENSEX tumbles 650 pts, NIFTY50 below 25,200 in noon deals; IIFL Finance, SpiceJet, Biocon among buzzing stocks
    4d ago18/11/2026, 1:49:02 pm
    SENSEX tumbles 650 pts, NIFTY50 below 25,200 in noon deals; IIFL Finance, SpiceJet, Biocon among buzzing stocks

    Glenmark Pharma shares advanced as much as 2.45% to hit an intraday high of ₹2,680 per unit on the NSE on Wednesday, after its subsidiary, Ichnos Glenmark Innovation, announced that it has submitted an Investigational New Drug (IND) application to the US FDA.

  • Thumbnail: Stocks to watch, Nov 18: Prime Focus, IIFL Finance, HCLTech, Prestige Estate, Ashoka Buildcon, Glenmark Pharma, IMFA
    4d ago18/11/2026, 8:45:44 am
    Stocks to watch, Nov 18: Prime Focus, IIFL Finance, HCLTech, Prestige Estate, Ashoka Buildcon, Glenmark Pharma, IMFA

    Shares of Ashoka Buildcon will be in focus after the company announced on November 17 that it has emerged as the lowest bidder (L-1) for a ₹1,465-crore project awarded by the National Highways Authority of India (NHAI), excluding GST.

Showing 1–2 of 2 articles